Steven G Deeks

Steven G. Deeks, MD, is a Professor of Medicine in Residence at the University of California, San Francisco (UCSF) and a faculty member in the Division of HIV, Infectious Diseases and Global Medicine at Zuckerberg San Francisco General Hospital. He is an internationally recognized expert on HIV pathogenesis and treatment. He is also now leading a large program focused on the pathogenesis and treatment of Long COVID.

Dr. Deeks has published over 700 peer-review articles, editorials and invited reviews on these and related topics. He is the contact principal investigator of DARE (the Delaney AIDS Research Enterprise), an NIH-funded international collaboratory aimed at developing therapeutic interventions to cure HIV infection. He recently directed the amfAR Institute for HIV Cure Research. In early 2020, he leveraged his HIV research program to construct the “Long-term Impact of Infection with Novel Coronavirus (LIINC)” cohort, which is now supporting dozens of studies addressing the impact of SARS-CoV-2 on health.

Dr. Deeks is a member of the American Society for Clinical Investigation (ASCI) and Association of American Physicians (AAP). He serves on the scientific advisory board for Science Translational Medicine and is the editor-in-chief of Current Opinion in HIV and AIDS. He is listed annually as one of the world’s most cited scientists for the past several years. In 2022, he received the Lifetime Achievement in Mentoring Award from UCSF.

In addition to his translational and clinical. investigation, Dr. Deeks maintains a primary care clinic for people living with HIV. Dr. Deeks has been engaged in HIV research and clinical care since 1993. He is an expert on the role of chronic inflammation in untreated and treated HIV disease. His research has several linked objectives, including: (1) to determine the mechanisms which contribute to this persistent inflammation during therapy, (2) to characterize the impact of persistent inflammation during antiretroviral therapy on end-organ disease and function, (3) to determine the impact of inflammation and immune dysfunction on HIV persistence during effective therapy and (4) to develop novel therapeutic interventions which reduce chronic inflammation and/or the size of the latent reservoir.